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Fig 1. Generalized prurigo nodularis. Patient 1 before (A) and after (B) a course of modified
Goeckerman therapy.
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hidradenitis suppurativa with response to
tumor necrosis factor inhibition
To the Editor: A 50-year-old man with refractory and
multitherapy-resistant hidradenitis suppurativa was
referred for evaluation after having been unsuccess-
fully treated with dapsone, oral isotretinoin, and
several cycles of antibiotics (clindamycin-rifampin,
tetracycline, cephalosporin) (Fig 1, A). He had
hidradenitis suppurativa since the age of 43 years,
wasoverweight andaheavy tobacco smoker, andhad
a medical history of acne, diabetes mellitus type 2,
arterial hypertension, hypertriglyceridemia, hiatal
hernia, depression, and psoriatic arthritis (PsA).
Active acne pustules and comedonal lesions were
observed on the face and neck; painful sterile
abscesses and hypertrophic scars were present at
the axillae and were classified as hidradenitis suppu-
rativa Hurley II stage of severity. The patient had also
erythematous scaly lesions on the scalp associated
with severe joint and diffuse inflammation leading to
the clinical diagnosis of PsA (Psoriasis Area Severity
Index score 1.2; DAS28-CRP4 5.78; pain visual analog
scale score 70). Two ulcerative lesions on his right leg
had a dusky erythematous undermined edge (Fig 1,
B), andwere clinically andhistologically diagnosed as
pyoderma gangrenosum after the exclusion of di-
agnoses including neutrophilic disorders, vasculopa-
thies, and infections. His quality of life was severely
hampered by disability and social discomfort.
Adalimumab is a highly specific tumor necrosis
factor (TNF)-alfa inhibitor, binding to both soluble
Fig 1. Clinical details of PsAPASH syndrome. Hidradenitis suppurativa: scarring and multiple
interconnected painful lesions localized at the axillae (Hurley stage II) (A). Ulcerative lesions
localized at the lower extremities clinically and histologically diagnosed as pyoderma
gangrenosum (B).
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proinflammatory cytokine with a pathogenetic role
in several immune-mediated diseases such as
psoriasis, hidradenitis suppurativa, and pyoderma
gangrenosum. The efficacy and safety of adalimu-
mab in treating PsA is largely demonstrated, whereas
limited evidence of its off-label use in treating
hidradenitis suppurativa, pyoderma gangrenosum,
or concomitant skin disorders has been
reported.1-3 Randomized, double-blind, placebo-
controlled studies have assessed the efficacy and
safety of adalimumab therapy in patients affected by
hidradenitis suppurativa.1,2
Adalimumab therapy was initiated at a dose of 40
mg every other week. A marked and rapid improve-
ment in PsA and psoriatic skin lesions (Psoriasis Area
Severity Index score 0; DAS28-CRP4 1.21; pain visual
analog scale score 0) with concomitant clinical
remission of hidradenitis suppurativa and pyoderma
gangrenosum was observed after 4 weeks of treat-
ment. The effect was durable over the 36 weeks of
treatment, and adalimumab was well tolerated.
Hidradenitis suppurativa is notoriously difficult
to treat. Currently available therapeutic options
including antibiotics (clindamycin-rifampin-tetra-
cycline), isotretinoin, and dapsone. If antibiotics
are ineffective, excisional surgery remains a valid
therapeutic approach. In our case, hidradenitis
suppurativa associated with PsA, acne, andpyoderma gangrenosum was successfully treated
with adalimumab. Adalimumab was administered
at the recommended dose for PsA therapy, leading
to the resolution of the clinical symptoms of
psoriasis and complete remission of hidradenitis
suppurativa and pyoderma gangrenosum. Similar
to the spectrum of recently described autoinflam-
matory syndromes, namely PASH ( pyoderma gan-
grenosum, acne, and hidradenitis suppurativa),
PAPA ( pyogenic arthritis, acne, and pyoderma
gangrenosum), and PAPASH ( pyogenic arthritis,
pyoderma gangrenosum, acne, and hidradenitis
suppurativa), the concomitant diagnosis of PsA,
pyoderma gangrenosum, acne, and hidradenitis
suppurativa may represent a new syndrome; the
acronym could be PsAPASH.4,5 As shown in this
case, TNF-alfa inhibition may represent a prom-
ising therapeutic strategy for treating multiple
concomitant skin disorders, such as that with
common pathogenic mechanisms. However,
further clinical observations will be helpful to
establish the prevalence of this clinical entity
and its treatment.
Rosita Saraceno, MD, Graziella Babino, MD,
Andrea Chiricozzi, MD, Arianna Zangrilli,
MD, and Sergio Chimenti, MD
Dermatology Department, University of Rome Tor
Vergata, Italy
Fig 1. Total mastectomy of the right breast revealed Paget
disease with underlying foci of ductal carcinoma in situ
(shown above). (Hematoxylin-eosin stain; original magni-
fication: 3100.)
Fig 2. In the axilla, atypical large cells with prominent
nuclei and pale cytoplasm are present diffusely within the
epidermis. (Hematoxylin-eosin stain; original magnifica-
tion: 3200.)
J AM ACAD DERMATOL
JANUARY 2015
e44 LettersFunding sources: None.
Disclosure: Dr Chimenti has been a consultant for
Abbvie (adalimumab manufacturer) and for
Merck (infliximab manufacturer). Dr Saraceno
has been a consultant for Abbvie. Drs Babino,
Chiricozzi, and Zangrilli have no conflicts of
interest to declare.
Correspondence to: Andrea Chiricozzi, MD,
Dermatology Department, University of Rome
Tor Vergata, Viale Oxford 81, 00133 Rome, Italy
E-mail: chiricozziandrea@gmail.com
REFERENCES
1. Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN,
Jemec GB. A double-blind placebo-controlled randomized trial
of adalimumab in the treatment of hidradenitis suppurativa.
Br J Dermatol 2011;165:391-8.
2. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the
treatment of moderate to severe hidradenitis suppurativa: a
parallel randomized trial. Ann Intern Med 2012;157:846-55.
3. Reddick CL, Singh MN, Chalmers RJ. Successful treatment of
superficial pyoderma gangrenosum associated with hidradeni-
tis suppurativawith adalimumab. DermatolOnline J 2010;16:15.
4. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS.
Hidradenitis suppurativa and concomitant pyoderma gangre-
nosum: a case series and literature review. Arch Dermatol
2010;146:1265-70.
5. Marzano AV, Trevisan V, Gattorno M, Ceccherini I, De Simone
C, Crosti C. Pyogenic arthritis, pyoderma gangrenosum, acne,
and hidradenitis suppurativa (PAPASH): a new autoinflamma-
tory syndrome associated with a novel mutation of the
PSTPIP1 gene. JAMA Dermatol 2013;149:762-4.
http://dx.doi.org/10.1016/j.jaad.2014.10.002
Synchronous Paget disease of the breast and
axilla
To the Editor: Mammary Paget disease (MPD) and
extramammary Paget disease (EMPD) are rare
acquired skin disorders having clinical features that
are similar to those of inflammatory or infectious skin
disorders. MPD is mostly associated with high-grade
ductal carcinoma in situ, whereas EMPD arises in
areas rich in apocrine glands. EMPD is classified into
primary and secondary EMPD; the latter is associated
with underlying malignancy and may arise as a result
of epidermal invasion of malignant adenocarcinoma
cells.
We report a rare case of synchronous Paget
disease. A 63-year-old woman presented concom-
itantly with crusting and erosion of the right nipple,
with brown plaques on the left axilla. Breast lesion
biopsy specimen indicated underlying foci of ductal
carcinoma in situ, which required total mastectomy
and sentinel lymph node biopsy. Axilla biopsy
specimen indicated EMPD, which required simpleresection of the left axilla lesion. Both tumors were
located in the epithelium (Figs 1 and 2), and axillary
sentinel lymph node biopsy specimen yielded
negative results. Because the operative margins
were negative and both tumors were staged as
TisN0M0, the treatment was deemed adequate.
Gross cystic disease fluid protein-15 and estrogen
receptor were expressed in the breast, but not in the
axilla tumor cells. Immunohistochemical and path-
ological analyses indicated that neither of these
were secondary metastatic lesions, but suggested
that they arose from independent tumorigenic
events.
Cases of synchronous MPD and EMPD are
extremely rare; to our knowledge, only 2 other cases
have been reported. This report is the first to
our knowledge that describes the simultaneous
diagnosis of synchronous Paget disease of the breast
and axilla.
